The Effects of Montelukast Sodium Combined with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol on Blood Gas Indicators,Inflammatory Factors,and Lung Function Indicators in COPD Patients
Objective To analyze the effects of montelukast sodium combined with budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol on blood gas indicators,inflammatory factors,and lung function indicators in patients with chronic obstructive pulmonary disease (COPD). Methods 80 COPD patients treated in Longnan First People's Hospital from January 2021 to September 2023 were divided into a control group (40 cases) and an observation group (40 cases) using a random number table method. Both groups of patients were treated with cough relief,anti infection,and oxygen therapy. The control group was treated with budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol,while the observation group was treated with budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol combined with montelukast sodium. The two groups were treated continuously for 3 months. Compare the clinical efficacy,inflammatory factors[interleukin-6 (IL-6),C-protein response (CRP)],lung function indicators[first second forced expiratory volume (FEV1),forced vital capacity (FVC),maximum respiratory flow (PEF),percentage of first second forced respiratory volume to expected value (FEV1％)],blood gas indicators[partial pressure of carbon dioxide (PaCO2),partial pressure of blood oxygen (PaO2)],and incidence of adverse reactions between two groups. Results The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment,the levels of IL-6 and CRP in the observation group were lower than those in the control group (P<0.05);the FVC,PEF,FEV1,and FEV1％ indicators in the observation group were higher than those in the control group (P<0.05);the observation group had lower PaCO2 indicators and higher PaO2 indicators (P<0.05). There was no statistically significant difference in adverse reactions between the two groups (P>0.05). Conclusion The combination of montelukast sodium and budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol can effectively improve respiratory distress symptoms and blood gas indicators in COPD patients,enhance lung function,reduce levels of inflammatory factors,and have a definite effect with high safety.
Chronic obstructive pulmonary diseaseMontelukast sodiumBudesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosolBlood gas indicatorsInflammatory factorsPulmonary function indicators
万方数据
维普
